Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Target Advancement Program, 2016
    Targeting the LRRK2-PAK6 Pathway in Parkinson's Disease

    Study Rationale:
    LRRK2 is one of the most attractive therapeutic targets in Parkinson's disease (PD); however, chronic doses of LRRK2 inhibitors result in side effects in pre-clinical models. We...

  • Improved Biomarkers and Clinical Outcome Measures, 2016
    Study of Drug Binding Sites in Alpha-synuclein Fibrils

    Objective/Rationale:
    This research aims to improve the potential to treat Parkinson's disease (PD) by using active molecules. Various small molecules that produce desired effects have been shown to...

  • Biomarkers Across Neurodegenerative Diseases, 2016
    Cross-disease Brain Image Modeling

    Study Rationale:

    Individuals with Alzheimer’s and Parkinson’s diseases share typical brain image patterns. The research field has long awaited an intelligent system that could interpret patterns...

  • Target Advancement Program, 2016
    Validation of Cyclin-G Associated kinase (GAK) as a Target for Parkinson's Disease

    Study Rationale:                   

    The project will investigate Cyclin-G associated kinase (GAK), a candidate risk gene for Parkinson’s disease (PD), based on genome-wide association studies (GWAS)...

  • Target Advancement Program, 2016
    Insights into LRRK2 Kinase Inhibitors

    Study Rationale:
    Mutations in LRRK2 cause an inherited form of Parkinson's disease (PD), and variations in LRRK2 can increase disease risk, indicating that the protein is key in the entire PD disease...

  • Therapeutic Pipeline Program, 2016
    Novel LRRK2 Antisense Oligonucleotides as a Therapy for Parkinson's Disease

    Study Rationale:
    LRRK2 gain-of-function gene mutations (R1441C and G2019S) are one of the most prevalent mutations contributing to inherited Parkinson's disease (PD). Altered LRRK2 function has also...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.